Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Cancer Cell. 2019 Aug 29;36(3):218–235. doi: 10.1016/j.ccell.2019.07.010

Figure 3. Transcriptomics and Genetics of the aPKCs in Cancer.

Figure 3.

(A) PRKCI and PRKCZ median expression across all tumor samples and paired normal tissues for 31 tumor types. Plots generated with GEPIA 2 (Tang et al., 2017). Tumor type nomenclature follows TCGA study abbreviations guidelines (https://gdc.cancer.gov).

(B) PRKCI and PRKCZ alterations in cancer using a curated set of non-redundant samples containing 159 studies with 35,693 patients and 36,917 samples for mutation data, and 158* studies with 27,410 patients and 28,457 samples for copy number variation data (cBioportal) (Cerami et al., 2012; Gao et al., 2013). *NEPC 2016 was omitted from CNV studies because it is not corrected for ploidy.

(C) Somatic mutation profile of PRKCI (cBioportal).

(D) Top 10 cancer types sorted by mutation frequency of PRKCI (cBioportal).

(E) Top 10 cancer types sorted by CNV frequency of PRKCI (cBioportal).

(F) Somatic mutation profile of PRKCZ (cBioportal).

(G) Top 10 cancer types sorted by mutation frequency of PRKCZ (cBioportal).

(H) Top 10 cancer types sorted by CNV frequency of PRKCZ (cBioportal).